CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 177 enrolled
Drug / intervention
ENCOREother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06271980
NCT06271980N/ACompleted

Predicting Long-Term Recurrence-Free and Overall Survival in Early-Onset Colorectal Cancer Survivors

City of Hope Medical Center·observational·Posted Feb 22, 2024·Updated Mar 12, 2024

In Brief

An observational study evaluating ENCORE for Colorectal Cancer Recurrent and 6 related conditions. Completed, enrolled 177 participants across 1 site.

Detailed Summary

Survivors of early-onset colorectal cancer (diagnosed before age 50) may experience colorectal cancer recurrence several years after curative-intent treatments, but clinical guidelines provide unclear guidance on endoscopic surveillance. This study aims to predict recurrence-free survival and overall survival, in survivors of early-onset colorectal cancer, using a tumor-based molecular assay based on microRNA (ribonucleic acid)

Study Details

Timeline

N/ACompletedFinished
202420252026
First PostedFeb 22, 2024
Enrollment StartApr 15, 2023
Primary CompletionFeb 1, 2024
TodayJul 1, 2026
Enrollment to primary: 10 monthsPosted 2.4 years ago

Interventions

ENCOREother

A panel of microRNA, whose expression level is tested in macro-dissected formalin-fixed and paraffin-embedded (FFPE) samples derived from the primary tumor.